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Class B1 G protein-coupled receptors (GPCRs) are important targets for many diseases,
including cancer, diabetes, and heart disease. All the approved drugs for this receptor
family are peptides that mimic the endogenous activating hormones. An understanding of
how agonists bind and activate class B1 GPCRs is fundamental for the development of
therapeutic small molecules. We combined supervised molecular dynamics (SuMD) and
classic molecular dynamics (cMD) simulations to study the binding of the calcitonin gene-
related peptide (CGRP) to the CGRP receptor (CGRPR). We also evaluated the association
and dissociation of the antagonist telcagepant from the extracellular domain (ECD) of
CGRPR and the water network perturbation upon binding. This study, which represents
the first example of dynamic docking of a class B1 GPCR peptide, delivers insights on
several aspects of ligand binding to CGRPR, expanding understanding of the role of the
ECD and the receptor-activity modifying protein 1 (RAMP1) on agonist selectivity.
Keywords: GPCR, CGRPR, CGRP, telcagepant, binding, molecular dynamics, supervised molecular dynamics
INTRODUCTION
G protein-coupled receptors, the largest family of cell surface receptors (Rosenbaum et al., 2009), are
targeted by approximatively 34% of all approved drugs (Hauser et al., 2017). Among the four major
classes of vertebrate GPCRs (A, B, C, and F), class B1 are endogenously activated by peptide
hormones involved in homeostatic control, e.g., of bone and energy metabolism, and cardiovascular
and immune responses (Hollenstein et al., 2014). Drugs acting on class B1 GPCRs could be
tremendously useful for the treatment of a range of disorders such as cancer, diabetes, heart disease,
hypercalcemia, obesity, and osteoporosis (Hollenstein et al., 2014).
Since the first active structure, published in 2017 (Liang et al., 2017), the structures of most class
B1 GPCRs in the active, G protein complexed, state have been determined through cryo-electron
microscopy (cryo-EM), advancing the knowledge of their activation mechanism (García-Nafría
and Tate, 2019; Liang et al., 2020b; Ma et al., 2020; Qiao et al., 2020; Liang et al., 2020a; Dong et al.,
2020; Duan et al., 2020; Zhou et al., 2020). GPCRs are characterized by a 7-transmembrane helix
domain (TMD) and, in class B1, by a N-terminal extracellular domain that contributes to agonist
binding, receptor activation, and signaling (de Graaf et al., 2017) (Figure 1A). Heterodimerization
with accessory receptor activity-modifying proteins (RAMPs, Figure 1A) can modulate hormone
binding and signaling (Hay and Pioszak, 2016) through an allosteric mechanism (Liang et al.,
2020a; Pham et al., 2019). The transmembrane spanning RAMPs interact with the calcitonin
receptor (CTR) and CTR-like (CLR) receptors at the transmembrane level, making contacts with
TM3, TM4 and TM5, and at the extracellular level, where they interface with the ECD (Figures
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1A,D). The heterodimer of CLR and RAMP1 displays selectivity
for calcitonin gene-related peptide and therefore constitutes the
prototypical CGRP receptor (CGRPR, Figures 1A,D) (Liang
et al., 2018a). The metastable binding of the neuropeptide CGRP
to CGRPR facilitates the intracellular G protein engagement,
which in turn allows the peptide to reach the final bound state
(Josephs et al., 2021). In this complex, CGRP inserts into the
receptor TMD core via a disulfide-bridged N-terminal loop and
short amphipathic α-helix, with an unstructured C-terminal tail
extended towards the ECD, where it forms an additional
anchoring point (Figures 1A,D). The aforementioned stable
binding mode can be achieved only after the engagement of the
G protein (De Lean et al., 1980; Chung et al., 2011; DeVree et al.,
2016), which allosterically facilitates an outward movement of
ECL3 and an upward shift of ECL2 (Josephs et al., 2021). The
CGRP-bound receptor, prior to G protein coupling, more closely
resembles the apo structure with stable binding of the peptide
C-terminus to the ECD, and where the peptide N-terminus only
transiently and dynamically engaged with the receptor core
(Josephs et al., 2021).
CGRP, which is involved in nociceptive transmission and
modulation of vasodilatation, is widely expressed in both
FIGURE 1 | (A) CGRPR is a heterodimer membrane protein composed of CLR (purple ribbon) and RAMP1 (gray ribbon); CGRP (orange van der Waals spheres)
binds to the TMD and extends towards the ECD. Agonist-bound CGRPR couples to Gs protein (green surface). (B) Chemical structure of the CGRPR antagonist
telcagepant. (C) CGRP primary sequence; the residues in the N-terminal helix are indicated in red. (D) Schematic representation of the events from the
heterodimerization between CLR and RAMPs to G protein signaling. The formation of complexes between CLR and different RAMPs generate receptors with
selectivity towards CGRP, AM1 or AM2; upon agonist binding, the trimeric Gs protein is recruited and activated, favoring the exchange between GDP and GTP at the
level of the Gsα subunit. After Gs subunits dissociation multiple intracellular signaling pathways are triggered (AC, adenylyl cyclase; PKA, protein kinase A; PLC,
phospholipase C; PI3K, phosphoinositide 3-kinases).
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peripheral and central regions of the nervous systems, including
the trigeminal vascular system (Rujan and Reynolds, 2019).
Multiple studies have shown that CGRP is associated with
migraine pathophysiology (Durham, 2006), making CGRP and
its receptor an important target for the treatment of migraine
(Rujan and Reynolds, 2019). Despite its involvement in the
underlying mechanisms associated with migraine, CGRP also
plays a protective role in the cardiovascular system (Kee et al.,
2018). Indeed, a novel peptide analogue of CGRP produces a
decrease in angiotensin II-induced hypertension as well as a
protective effect against heart failure (Aubdool et al., 2017).
The heterodimers of CLR and RAMP2 or RAMP3, instead, are
more selective for adrenomedullin (AM) and adrenomedullin 2
(AM2) peptides and constitute the AM1 and AM2 receptors,
respectively (AM1R and AM2R, Figure 1D) (Hay and Pioszak,
2016; Hay et al., 2018; Liang et al., 2020a).
The role played byCGRP inmigraine has stimulated the pursuit
of agents able to block CGRPR activation (Rujan and Reynolds,
2019). Clinical approval of agents targeting this system was first
achieved for monoclonal antibodies targeting CGRP or CGRPR.
To date, there are three approved monoclonal antibodies against
CGRP (galcanezumab, fremanezumab and eptinezumab), and one
against CGRPR [erenumab, the first FDA-approved monoclonal
antibody targeting a GPCR (Garces et al., 2020)]. Erenumab binds
to the ECD of CGRPR, interacting with both CLR and RAMP1
(Garces et al., 2020). The pursuit of orally bioavailable CGRPR
antagonists led to the discovery of phenylcaprolactam derivatives.
Ubrogepant became the first-in-class oral CGRP antagonist
approved for the acute treatment of migraine (December 2019)
(Scott, 2020b). This was followed by the approval of rimegepant in
February 2020 making it the second approved acute anti-migraine
small-molecule drug and the first fast-acting orally disintegrating
tablet (Scott, 2020a).
Telcagepant (Figure 1B), a phenylcaprolactam prototype, binds
to the ECD of CGRPRwith aKi of 0.8 nM, inhibiting the binding of
the CGRP C-terminal domain (Paone et al., 2007; Salvatore et al.,
2008; Aksoydan and Durdagi, 2021). CGRP displays biphasic
competition with telcagepant (Moore et al., 2009), consistent
with the two-step binding mechanism proposed for class B1
GPCR peptides (Pal et al., 2012). According to this model,
preliminary interactions between the receptor ECD and the
ligand C-terminal domain facilitates the binding of the
N-terminal domain within the receptor transmembrane domain
(TMD) (Castro et al., 2005; Pal et al., 2012). This increases the local
concentration of the N-terminal activation domain of the peptide
in the proximity of the target, productively orienting the peptide
and favoring the transition of the TMD core from an inactive to an
active conformation. The distinct timescales characterizing the two
different steps (microsecond and several millisecond, respectively
(Castro et al., 2005) suggest that the productive engagement of the
peptide N-terminal domain with the receptor TMD core is the
rate-limiting step for agonist binding and receptor activation.
However, at high concentrations of CGRP, in the presence of
telcagepant, monophasic saturation curves are observed (Moore
et al., 2009). This is putatively due to an ability of the CGRP
N-terminal domain to bind to the TMDof the receptor without the
prior formation of the metastable complex between the ECD and
the peptide C-terminal domain.
GPCR activation mechanisms also involve water molecules
within the TMD (Venkatakrishnan et al., 2019), including the
orthosteric (endogenous) ligand binding site (Higgs et al., 2010),
and the G protein binding site. From a drug design perspective,
discerning whether a region of the binding site is solvated by
stable or unstable water molecules can drive the development of
tighter or more selective binders. Chemical modifications can be
designed to displace unstable water molecules or further stabilize
stable ones (Ladbury, 1996; Bortolato et al., 2013).
In the present study, we employed supervised molecular
dynamics (Sabbadin and Moro, 2014; Cuzzolin et al., 2016;
Salmaso et al., 2017; Deganutti et al., 2020) and classic
molecular dynamics simulations to sample the binding of
CGRP (Figures 1A,C) and the inhibitor telcagepant
(Figure 1B) to CGRPR. The dynamic docking of CGRP to the
TMD highlighted residues located within loop 4 of the ECD as a
possible key player in the association mechanism. Simulated
telcagepant binding and unbinding paths identified residues
involved in metastable binding states as well as interactions
that could constitute putative kinetic bottlenecks in formation
of the high-affinity binding pose. We also simulated the active
state CGRPR after removal of any ligand to compare the hydrated
regions of the receptor before and after CGRP or telcagepant
binding to assess potential changes to CGRPR hydration that
occur upon ligand binding.
METHODS
Telcagepant Force Field Parameters
All the systems (Table 1) were prepared for MD using the
CHARMM36 (Huang and MacKerell, 2013; Huang et al.,
2017)/CGenFF 3.0.1 (Vanommeslaeghe et al., 2012;
Vanommeslaeghe and MacKerell, 2012; Yu et al., 2012) force
TABLE 1 | Summary of the MD simulations performed and analyzed.
Ligand Receptor structure Simulations performed # Replicas Simulation time analyzed (µs)
Telcagepant CGRPR(CLR:RAMP1) ECD SuMD binding 4 0.7
Telcagepant CGRPR(CLR:RAMP1) ECD SuMD unbinding 5 1.18
SuMD path sampling
CGRP CGRPR(CLR:RAMP1) SuMD binding 1 1.65
cMD
SuMD path sampling
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field combination. The initial telcagepant force field, topology and
parameter files were obtained from the ParamChem webserver
(Vanommeslaeghe and MacKerell, 2012).
Protein Preparation
In order to speed up simulations involving CGRP, only the Gs
C-terminal helix (residues N371-L394) of the G protein from the
PDB entry 6E3Y was retained, after modelling of the missing
segments in the ICL3 (residues 324–328), ECL3 (residues
356–363), ECD (residues 55–63), and CGRP (residues 24–26)
as reported in our previous work (Liang et al., 2018a). The
resulting active CGRP:CLR:RAMP1 complex was then
prepared as follows. Hydrogen atoms were added by means of
the pdb2pqr (Dolinsky et al., 2004) and propka (Olsson et al.,
2011) software (considering a simulated pH of 7.0); the
protonation of titratable side chains was checked by visual
inspection. The resulting receptor was inserted in a square
100 Å × 100 Å 1-palmitoyl-2-oleyl-sn-glycerol-3-
phosphocholine (POPC) bilayer (previously built by using the
VMD Membrane Builder plugin 1.1, Membrane Plugin, Version
1.1. at http://www.ks.uiuc.edu/Research/vmd/plugins/
membrane/), through an insertion method (Sommer, 2013).
The receptor orientation was obtained by superposing the
coordinates on the corresponding structure retrieved from the
OPM database (Lomize et al., 2006). Lipids overlapping the
receptor transmembrane helical bundle were removed and
TIP3P water molecules (Jorgensen et al., 1983) were added to
the simulation box by means of the VMD Solvate plugin 1.5
(Solvate Plugin, Version 1.5. at http://www.ks.uiuc.edu/Research/
vmd/plugins/solvate/). Finally, overall charge neutrality was
reached by adding Na+/Cl− counter ions up to the final
concentration of 0.150 M), using the VMD Autoionize plugin
1.3 (Autoionize Plugin, Version 1.3. at http://www.ks.uiuc.edu/
Research/vmd/plugins/autoionize/).
Simulations involving telcagepant were carried out
considering only the CGRPR extracellular domain (CLR
residues Q33ECD-T1311.29, RAMP1 residues E29-P114).
Telcagepant was placed about 30 Å away from the ECD and
the system was solvated and neutralized as described above.
System Equilibration and General MD
Settings
The MD engine ACEMD (Harvey et al., 2009) was employed for
both the equilibration and productive simulations. The
equilibration of the CGRP:CLR:RAMP1 complex was achieved
in isothermal-isobaric conditions (NPT) using the Berendsen
barostat (Berendsen et al., 1984) (target pressure 1 atm) and the
Langevin thermostat (Loncharich et al., 1992) (target temperature
300 K) with low damping of 1 ps−1. A four-stage procedure was
performed (integration time step of 2 fs): first, clashes between
protein and lipid atoms were reduced through 2000 conjugate-
gradient minimization steps, then a 2 ns long MD simulation was
run with a positional constraint of 1 kcal mol−1 Å−2 on protein
and lipid phosphorus atoms. During the second stage, 20 ns of
MD simulation was performed constraining only the protein
atoms, while in the last equilibration stage, positional constraints
were applied only to the protein backbone alpha carbons, for a
further 20 ns.
ECD equilibration was achieved in two steps: after 500 cycles
of conjugate-gradient minimization, the system was simulated for
5 ns, employing an integration time step of 2 fs, in the isothermal-
isobaric conditions (NPT). The system comprising telcagepant
and ECD was equilibrated in the NPT ensemble for 2 ns
restraining the protein backbone alpha carbons.
Productive trajectories (Table 1) were computed with an
integration time step of 4 fs, using the hydrogen mass
repartition (Hopkins et al., 2015), in the canonical ensemble
(NVT). The target temperature was set at 300 K, using a
thermostat damping of 0.1 ps−1; the M-SHAKE algorithm
(Forester and Smith, 1998; Kräutler et al., 2001) was employed
to constrain the bond lengths involving hydrogen atoms. The cut-
off distance for electrostatic interactions was set at 9 Å, with a
switching function applied beyond 7.5 Å. Long range Coulomb
interactions were handled using the particle mesh Ewald
summation method (PME) (Essmann et al., 1995) by setting
the mesh spacing to 1.0 Å.
Metadynamics Simulation of CGRP:CLR:
RAMP1 Complex
The CGRP:CLR:RAMP1 complex was subjected to a
metadynamics simulation to release the agonist from the
bound state and relax the ECD in the absence of bound
ligand. The well-tempered version of metadynamics (Barducci
et al., 2008) was performed employing PLUMED 2.3 (Tribello
et al., 2014), biasing the distance between the residues C7-L16
(CGRP) and K1341.32-V3917.64 (CLR) centroids. Gaussian energy
functions were seeded every 1 ps (height  0.1 kcal/mol, width 
0.1 Å, with a bias factor  20), at a simulated temperature of
300 K, until the biased distance reached 50 Å. This final frame was
used as the starting point for SuMD binding simulations
of CGRP.
The Supervised MD Protocol
The supervised molecular dynamics (SuMD) is an adaptive
sampling method (Deganutti and Moro, 2017a) for speeding
up simulation of the binding (Cuzzolin et al., 2016; Deganutti
et al., 2015; Deganutti and Moro, 2017b; Salmaso et al., 2017;
Sabbadin and Moro, 2014; Bower et al., 2018; Bissaro et al., 2019;
Bissaro et al., 2020) and unbinding processes (Deganutti et al.,
2020). In the first SuMD implementation (Sabbadin and Moro,
2014; Cuzzolin et al., 2016), sampling is gained without the
introduction of any energetic bias, by applying a tabu–like
algorithm to monitor the distance between the centers of mass
(or the geometrical centers) of the ligand and the predicted
binding site or the receptor. However, the supervision of a
second metric of the system can be considered (Atanasio
et al., 2020). A series of short unbiased MD simulations are
performed, and, after each simulation, the distances (collected at
regular time intervals) are fitted to a linear function. If the
resulting slope is negative (for binding), the next simulation
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step starts from the last set of coordinates and velocities
produced, otherwise if the slope is positive, the simulation is
restarted by randomly assigning the atomic velocities.
Settings for SuMD Binding
The binding of telcagepant to the CGRPR ECD was obtained by
supervising the distance between the ligand and CGRPR residue
W72ECD (which is roughly in the center of the telcagepant
binding site). A series of 500 ps-long time windows were
simulated until the distance reached a value of less than 4 Å.
Frames were saved every 50 ps and used to interpolate the linear
function of the distance during the simulated 500 ps.
To simulate the CGRP binding to CGRPR, the distance
between the centroids of residues C7-L16 (CGRP) and
K1341.32-V3917.64 (corresponding to the CLR TMD) was
supervised. Four replicas were started from the last frame
extracted from the metadynamics, by moving CGRP further
away from the receptor and randomly reorienting it. After
250 ns of productive SuMD simulations time, the replica with
lower RMSD values to the cryo-EM structure (CGRP residues
C7-L16) was used to seed four 1 µs-long classical MD (cMD)
simulations. This unsupervised step was performed to facilitate
the reorganization of the CGRP:CGRPR metastable states
minimizing external influence due to the supervision. The
cMD replica characterized by the lowest RMSD value to the
cryo-EM structure (CGRP residues C7-L16) was used as a
starting point for four additional SuMD binding simulations
until visual inspection confirmed appropriate binding of the
CGRP N-terminus.
Settings for SuMD Unbinding of Telcagepant
The frame with the lowest RMSD value to the X-ray complex
3N7R (ter Haar et al., 2010), representing the ECD in complex
with telcagepant, was extracted from SuMD binding trajectories
and used as a starting point for CGRPR ECD-telcagepant
unbinding simulations (ECD residues Q33ECD-T1311.29,
RAMP1 residues E29-P114). A double supervision was
performed: both of the ligand-W72ECD distance and the
number of water oxygen atoms within 4 Å of protein atoms
and that are hydrogen bonding with telcagepant (if the slope of
the linear function plotted on each of the two data series was
positive then the time window was productive). The protocol for
unbinding differs from the original SuMD binding algorithm, in
that the length (Δt) of the short simulations performed increased
along the unbinding pathway, according to the formula:
Δt  Δt0Nti (1)
Δt0 is the duration of the very first MD time window and Nti
represents a factor that is picked from three user-defined values
(Nt1, Nt2, and Nt3), according to the last ligand-protein distance
detected (Deganutti et al., 2020). Three distance threshold values
(D1, D2, and D3) were set and the ligand-protein distance (rL) at
the end of each MD run was compared to these threshold values,
allowing a decision on the value of the Nti factor according to the
following conditions:
rL ≤ D1 → Nti  1 (2)
D1 < rL ≤ D2 → Nti  Nt1 (3)
D2 < rL ≤ D3 → Nti  Nt2 (4)
D3 < rL → Nti  Nt3 (5)
The goal of increasing the simulation time window (Δt in Eq.
1) along the unbinding pathway is to facilitate the sampling of
metastable states, which could otherwise be poorly visited.
Frames were saved every 50 ps. The initial time window length
was 300 ps, with Nt1, Nt2, and Nt3 set to 3, 6, and 10. Values of 5,
8, and 10 Å were used as D1, D2, and D3 distances.
The unbinding was iterated until no ligand-protein van der
Waals contact was detected by means of the GetContacts scripts
tools (https://getcontacts.github.io). The ligand-protein distance
and the number of water oxygen atoms within 4 Å of protein
donor/acceptor atoms were computed using PLUMED 2.3. After
each productive MD time window, GetContacts was employed to
detect and update the protein atoms involved in hydrogen bonds
with the ligand, considering a distance of 3.5 Å and an angle value
of 120° as geometrical cut-offs. Notably, if no hydrogen bond
between the ligand and the protein was present at the end of a
productive MD time window, then protein atoms involved in
water-mediated or van der Waals interactions were considered.
SuMD Path Sampling Protocol
SuMD path sampling (Deganutti et al., 2021) (Table 1) was
performed considering the output from each SuMD replica, for
binding of both CGRP and telcagepant and the unbinding of
telcagepant. Each trajectory was aligned on the protein alpha
carbon atoms and the frames were clustered according to the
ligand RMSD to the starting positions (bin of 1 Å). A frame from
each group was randomly extracted and used as a starting point
for 20 ns (for telcagepant unbinding) or 30 ns (for CGRPR
binding) cMD simulations.
Analysis of the MD Trajectories
Only the MD trajectories from the SuMD path sampling were
analyzed in the case of telcagepant unbinding and CGRPR
binding. Interatomic contacts and root mean square deviations
(RMSD) were computed using VMD (Humphrey et al., 1996). A
contact was considered productive if the distance between two
atoms was less than 3.5 Å. Ligand-protein hydrogen bonds were
detected using the GetContacts scripts tool (https://getcontacts.
github.io), setting a hydrogen bond donor-acceptor distance of 3.
5 Å and an angle value of 120° as geometrical cut-offs. Contacts
and hydrogen bond persistency are quantified as the percentage
of frames (over all the frames obtained by merging the different
replicas) in which protein residues formed contacts or hydrogen
bonds with the ligand.
Distances between atoms were computed using PLUMED 2.3
(Tribello et al., 2014). The molecular mechanics energy combined
with the generalized Born surface area (MM/GBSA) was
computed with the MMPBSA.py (Miller et al., 2012) script
(AmberTools17 suite at http://ambermd.org/) after
transforming the CHARMM psf topology files to an Amber
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prmtop format using ParmEd (documentation at http://parmed.
github.io/ParmEd/html/index.html).
Detection of hydrated spots within CGRPR in the peptide-
bound active state (PDB: 6E3Y) was performed on 100 ns long
cMD simulations by means of AquaMMapS (Cuzzolin et al.,
2018), in the holo state or following removal of CGRP from the
complex. This allowed taking into account the flexibility of the
systems and thermal fluctuation within the orthosteric
binding site.
Numbering System
Throughout the manuscript, the class B1 GPCRWootten residue
numbering system (Wootten et al., 2013) is displayed as
superscripts to the CLR residues numbers.
FIGURE 2 | CGRP dynamic docking. (A) CGRP binding energy landscape; x axes report the distance between the TMD centroid and the CGRP N-terminal helix
(the metastable macrostate, MS, is indicated, alongside the deep bound states OS); (B) binding path of the centroid of the CGRP N-terminal helix, colored according to
the interaction energy with CGRPR; (C) representative configuration from the macrostate MS. CGRPR ECD loop 4 forms salt bridges with CGRP R11 and R18; (D)
representative configuration from the deep bound states OS. Electrostatic interactions are depicted as red dashed lines, while hydrophobic contacts are depicted
as cyan transparent surfaces. (E) CGRP-CGRPR contacts plotted on CGRPR surface and colored according to the occupancy (% MD frames) of the interactions; (F)
CGRP-CGRPR contacts plotted on CGRPR atoms and colored according to the occupancy (% MD frames) of the interactions.
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RESULTS
Binding Path of CGRP
The current study focuses on the mechanism of binding for the
N-terminal domain of CGRP that is critical to activation of CGRPR.
Recent work elucidated the structures of apo and peptide-bound
CGRPR in the absence of transducer protein (Josephs et al., 2021)
and revealed that, as expected, the peptide C-terminus is stably engaged
with the ECD of the receptor, albeit that the ECD is highly dynamic.
However, the N-terminus of the peptide only transiently engages with
the core of the receptor. As such, there is a gap in understanding of how
the CGRP N-terminus (that includes the disulfide-bridged N-terminal
loop and short α-helix that extends from this loop) engages with
CGRPR to reach the fully-active, G protein-coupled complex that has
been experimentally characterized by cryo-EM (Liang et al., 2018a).
During the dynamic docking of the N-terminal helix of CGRP
(Supplementary Video S1), the unstructured C-terminal domain
spontaneously approached the ECD, forming transitory interactions
between F37CGRP andW72ECD orW84RAMP1 (Supplementary Table
S1). High flexibility of the CGRP C-terminal segment bound to the
receptor was also suggested by MD simulations of the active, CGRP:
CGRPR:G protein complex (Liang et al., 2018a). These contacts, along
with the hydrogen bond between T122ECD backbone and the terminal
NH2 at F37
CGRP, are present in the cryo-EM structure and are likely
important for the first step of CGRP binding. Very few interactions
were formed with RAMP1 (Figures 2C,D; Supplementary Figures
S1A,B; Supplementary Tables S1, S2).
CGRP transition from the bulk solvent to the orthosteric site
within the TMD was progressively stabilized by interactions of
the peptide and receptor (Figures 2A,B). The first contacts
between CGRP and CLR were formed at the level of the tunnel
entrance shaped by the ECD, TM1, TM2, and ECL1 (Figures
2C–E, Supplementary Figures S1A,B). The peptide disulfide-
bridged N-terminal loop (residues 1–7) formed transitory polar
interactions with Q33ECD, Q93ECD, D90ECD, N200ECL1,
N201ECL1, and Q202ECL1, before V8CGRP, L12CGRP, and
FIGURE 3 |Water network perturbation upon CGRP and telcagepant binding. (A) hydration positions in the TMD of the active CGRPR (white ribbon, representative
conformation from the first frame of MD simulation), after removal of ligand; CLR and RAMP1 are shown as transparent white and grey ribbons, CGRP from PDB 6E3Y is
superimposed (by superimposing TMD scaffolds) and shown as a transparent orange ribbon; (B) hydration positions in the holo CGRPR TMD (representative
conformation from the first frame of MD simulation). CLR and RAMP1 are shown as transparent white and grey ribbons, CGRP as an orange ribbon; (C) hydration
positions in the ECD of the active CGRPR, after removal of any ligand; CLR and RAMP1 are shown as transparent white and grey ribbons, CGRP from PDB 6E3Y and
telcagepant from PDB 3N7R are superimposed and shown as transparent orange ribbon and pink sticks, respectively. In (A–C) the color scale of the hydrated spots
corresponds to the occupancy of water molecules during the MD simulation (in dark blue the maximum occupancy).
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L15CGRP on the hydrophobic side of the amphipathic α-helix of
CGRP engaged the side chains of V1351.33, L1391.37, F1421.40,
L1952.68 in hydrophobic contacts. While the initial polar
interactions are not present in the CGRP:CGRPR:Gs cryo-EM
structure, the latter hydrophobic contacts are reflected in the
experimental structure, and throughout the binding simulation
acted as a glidant, favoring the peptide insertion into the TMD.
While entering the TMD orthosteric site, CGRP formed further
interactions with D94ECD, F92ECD, W3546.58, D3667.39, and
H3707.43 (Figures 2C,D; Supplementary Figures S1A,B;
Supplementary Tables S1, S2). In the intermediate
macrostate, MS (Figure 2A), the agonists sampled several
metastable configurations before reaching the bound
orthosteric microstate, OS (Figure 2A). This latter state was
in remarkable agreement with the experimental coordinates of
the fully active complex (Liang et al., 2018a) (Supplementary
Video S1). The RMSD of the CGRP Cα carbons to the cryo-EM
conformation of CGRP, indeed, reached values lower than 1 Å
FIGURE 4 | Telcagepant dynamic docking. (A) Telcagepant binding energy landscape (the metastable macrostates, MS1 and MS2, are indicated, alongside the
bound states, OS, corresponding to the pose in solved structure); (B) binding paths of the centroid of telcagepant, colored according to the interaction energy with
CGRPR (the metastable macrostates, MS1 and MS2, are indicated, alongside the stable bound states OS); (C) Telcagepant-CGRPR contacts plotted on CGRPR
surface and colored according to the occupancy (% MD frames) of the interactions; (D) Telcagepant-CGRPR contacts plotted on CGRPR atoms and colored
according to the occupancy (% MD frames) of the interactions; (E) representative configuration from the macrostate, MS1; (F) representative configuration from the
macrostate, MS2; (G) representative configuration from the bound states OS. Electrostatic interactions are depicted as red dashed lines, while hydrophobic contacts are
shown as cyan transparent surfaces.
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(3 Å considering the side chain heavy atoms of the peptide helix,
Supplementary Figure S2). The agonist residues forming the
most frequent interactions during the binding (considering the
whole binding trajectory) were D3CGRP, T4CGRP, T6CGRP,
T9CGRP, H10CGRP, R11CGRP, L15CGRP, R18CGRP, and F37CGRP
(Supplementary Figures S1C,D; Supplementary Tables
S1, S2).
The gradual engagement of the top of TM6, TM7 and ECL3 by the
peptide N-terminal domain was accompanied by an inward
movement of ECL3 (Supplementary Video S1); ECL3 is
important for CGRPR signaling (Barwell et al., 2011) but its
dynamics during receptor activation are still unclear. A
comparison between the consensus maps of CGRP:CGRPR and
CGRP:CGRPR:Gs complexes (Josephs et al., 2021) shows that the
FIGURE 5 | Telcagepant dynamic unbinding. (A) Telcagepant unbinding energy landscape (the metastable macrostates, MS, are indicated, alongside the stable
bound states OS); (B) unbinding paths of the centroid of telcagepant, colored according to the interaction energy with CGRPR (the metastable macrostates, MS, are
indicated, alongside the stable bound states, OS); (C) Telcagepant-CGRPR contacts plotted on CGRPR surface and colored according to the occupancy (% MD
frames) of the interactions; (D) Telcagepant-CGRPR contacts plotted on CGRPR atoms and colored according to the occupancy (% MD frames) of the
interactions; (E) representative configuration from the stable bound state, OS; (F) representative configuration from the metastable macrostate, MS. Electrostatic
interactions are depicted as red dashed lines, while hydrophobic contacts are shown as cyan transparent surfaces.
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location of the top of TM6/7/ECL3 in the former structure partially
overlaps with the location of the peptide binding pocket in the active
CGRPR. Analysis of the conformational dynamics of the CGRP:
CGRPR complex revealed that the top of TM6/7/ECL3 dynamically
opens and closes in association with transient interaction of the
peptide N-terminus and the TMD core (Josephs et al., 2021). This
reinforces the concept that the presence of the G protein at the
intracellular side of the receptor is needed to allosterically stabilize
peptide N-terminal domain binding to the receptor core. Our
simulations started from the fully active CGRPR in complex with
both CGRP and the Gα helix 5, which could favor the productive
engagement of ECL3 with the peptide N-terminus.
The binding energy landscape of CGRP shows low prevalence of
states betweenMS andOS (Figure 2A), indicative of the presence of a
transition state. In MS, the positively charged agonist residues
R11CGRP, R18CGRP formed electrostatic interactions with the side
chains of loop 4 residues D90ECD and D94ECD (Figure 2E;
Supplementary Figure S1D). In OS, the same CGRP residues
interacted with D287ECL2, E357ECL3 and R355ECL3 (Figure 2F;
Supplementary Table S2). It follows that during the transition
from MS to OS, the ionic network between CGRP and D90ECD,
D94ECD becomes disrupted to allow new interactions with the TMD.
In the TMD of the active CGRPR, after removal of any ligand
(Figure 3A), two hydration clusters were detected in close proximity
to ECL2 (namely ECL2 water clusters “up” and “down,” according to
the position respective to the backbone of the loop). A further
hydrated region was detected near ECL3 (ECL3 water cluster).
Two structural water molecules are positioned close to the
conserved polar core of the receptor (N1872.60 and TM2-TM4
water molecules in Figure 3A); the polar core is important for
class B1 receptor activation and biased agonism (Wootten et al.,
2013; Wootten et al., 2016; Yin et al., 2017). Upon binding and
insertion of the N-terminal helix within the TMD, CGRP stabilizes
several water molecules located in proximity to ECL2 and ECL3
(Figure 3B), without overlapping any hydrated region present in the
active CGRPR in the absence of ligand. Interactions between CGRPR
and the TMD changes the hydration of the TMD by destabilizing the
N1872.60 and TM2-TM4 water molecules, which are not detected in
the peptide-occupied complex (Figure 3B). Overall, these data suggest
an efficient solvation profile and formation of a favorable water
network during the binding of CGRP.
Telcagepant Binding and Unbinding Paths
The antagonist telcagepant (Figure 1B) binds into a pocket delimited
by the ECD and RAMP1 (ter Haar et al., 2010). During dynamic
docking simulations (Figure 4; Supplementary Video S2), the ligand
rapidly reached the crystallographic conformation following two
possible paths (Paths A and B in Figure 4B) and forming
intermediate metastable states in correspondence of macrostates,
denoted MS1 and MS2 (Figures 4A,B). The most persistent
contacts with the receptor were formed around the binding site
(Figures 4C,D; Supplementary Tables S3, S4) and comprised
interactions with side chains of W72ECD, I41ECD, M42ECD, R38ECD,
Q45ECD, W74RAMP1, and W84RAMP1, which are also involved in the
final bound state. Besides the hydrogen bonds with W72ECD and the
backbone of T122ECD, the antagonist formed transitory polar
interactions with N128ECD, R119ECD, and W121ECD
(Supplementary Figure S3; Supplementary Table S4). Binding
Path A was facilitated by interactions with the ECD helix 1
residues Q33ECD, V36ECD, T37ECD, K40ECD (Figure 4E). Binding
Path B involved interactions with the RAMP1 residues N31RAMP1 and
F83RAMP1, located over the binding site (Figure 4F). Consistent with
mutagenesis studies (Moore et al., 2010), no significant hydrogen
bonds were formed between telcagepant and R67RAMP1, D71RAMP1,
and E78RAMP1 (Supplementary Table S4).
Unbinding simulations (Figure 5; Supplementary Figure S4;
Supplementary Tables S5, S6) sampled one notable metastable
macrostate (MS in Figures 5A,B) close to the bound configuration
observed in the static crystallographic structure (ter Haar et al., 2010)
(OS in Figures 5A,B). The transition betweenOS andMS took place
in the early stages of ligand dissociation and involved the rupture of
the hydrogen bonds with the backbone of T122ECD in favor of new
transient interactions with D94ECD and N128ECD (Figures 5E,F).
After release from the hydrophobic interactions between the 1,2-
dichlorobenzene group and W74RAMP1, W84RAMP1, and M42ECD,
telcagepant followed two possible unbinding routes from MS
(Figure 5B): unbinding Path A roughly represented the inverse
of binding Path A, while unbinding Path B followed an alternative
direction, away from RAMP1, which involved interactions with
W72ECD.
The ECD is the first site of stable contacts for class B1 peptides
during the proposed two-stage peptide agonist binding (Hoare,
2005), as well as the target of the antagonist telcagepant
(Figure 3C). In the active CGRPR, following removal of the
ligand, AquaMMapS analysis highlighted two clusters of stable
water molecules in the proximity of T122ECD (Figure 3C), within
the binding site of telcagepant and the distal residues of the CGRP
C-terminal domain. The backbone of T122ECD forms hydrogen
bonds with either the primary amide of the CGRP C-terminal
residue F37CGRP or with the phthalimide moiety of telcagepant. It
follows that both ligands likely displace stable water molecules to
form hydrogen bonds with the T122ECD backbone. Upon binding,
telcagepant extends the difluorophenyl moiety into a hydrophobic
pocket and displaces unstable water molecules, as suggested by the
absence of hydrated spots in this region of ECD (Figure 3C).
DISCUSSION
Recently resolved class B1 GPCR structures reveal a heterogenous
conformational landscape that involves the extracellular elements of
the receptor (Liang et al., 2020b; Zhang et al., 2020). For example,
different glucagon-like peptide receptor (GLP-1R) agonists imprint
divergent orientations of the ECD and alternative conformations of
the top of TM1, TM6, TM7, ECL2, and ECL3. Some of these
structural features, such as an outward conformation of ECL3,
appear linked to biased agonism of different ligands (Liang et al.,
2018b; Zhang et al., 2020).
The structural mechanism underlining the agonist two-step
binding and class B1 receptor activation is still unclear. The recent
structures of CGRPR in apo and CGRP-bound (before G protein
coupling) forms have delivered new insights into the transition from
the resting to the fully active state of the receptor (Josephs et al., 2021).
Interestingly, in the consensus cryo-EM maps only minor
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conformational changes in the backbone of the receptor were
observed before and after the binding of CGRP. Given the
intrinsic flexibility that characterizes GPCRs (Latorraca et al.,
2017), orthogonal methods such as hydrogen-deuterium exchange
mass spectrometry (Yang et al., 2015; Josephs et al., 2021), 3D variance
analysis of cryo-EM conformational continuums (Liang et al., 2020a;
Dong et al., 2020; Zhang et al., 2020; Josephs et al., 2021) and
molecular dynamics simulations (Deganutti et al., 2019) are
required to characterize CGRPR molecular motions and advance
the understanding of its pharmacology.
The adaptive sampling protocol employed in the current study
focused on the peptide N-terminal approach to the CGRPR TMD,
and therefore did not interrogate the preliminary interactions between
the ECD and the peptide C-terminal domain. The simulation of the
complete two-stage binding mechanism requires a more thorough
computational sampling and should take into account the secondary
structure characterizing the class B1 peptides in solution before any
interaction with the ECD occurs. GLP-1, secretin (Sec), glucagon
(GCG), pituitary adenylate cyclase activating polypeptide (PACAP),
vasoactive intestinal polypeptide (VIP), parathyroid hormone 1
(PTH1), and corticotrophin-releasing factor (CRF) bind with an
extended α-helix conformation spanning from the TMD to the
ECD binding sites. However, in solution, many of them present a
disordered N-terminal segment (Gronenborn et al., 1987; Neidigh
et al., 2001). This suggests that the formation of the α-helix is a
hallmark of the binding. On the other hand, agonists from the
calcitonin sub-family, such as CGRP, in solution show only partial
folding of the N-terminal in α-helix motif (Breeze et al., 1991) and
engage their target by retaining this structural organization.
This structural conservation between solution and receptor-bound
CGRP structures rules out any major conformational changes of the
CGRP during the binding, reinforcing our findings. RAMPs
allosterically alter the dynamics of the ECD, ECL2 and ECL3 and
the signaling profile of CLR, in a peptide-dependent manner (Liang
et al., 2020a). However, the structural reasons for the binding
selectivity exerted on CLR is still unclear. We speculate that
different RAMPs may modulate the affinity of CLR agonists by
driving divergent metastable states of ECD loop 4 during binding
to the TMD. The membrane-proximal linker region of the RAMP1
(residues 102–118, Figures 1A, 2D,E) is an important contributor to
the allosteric modulation of CLR (Liang et al., 2020a). The different
rotameric states of D113RAMP1 in the apo and CGRP-bound states of
CGRPR (Josephs et al., 2021) along with dynamic differences in this
region reported for the RAMPs (Supplementary Figure S5) suggests
that the flexibility of the linker could play a more complex role in
selectivity of agonist binding. The position of ECD loop 4 in the
CGRP:CGRPR:Gs, AM:AM1R:Gs, AM:AM2R:Gs and AM2:AM2R:Gs
complexes (Liang et al., 2020a) is different, implying a possible
correlation with the linker region. The exchange of the RAMP1
linker with the RAMP2 linker produces a loss of CGRP potency
ascribable to a correlated dynamic between the ECDand theGprotein
(Liang et al., 2020a).
Our simulations showed that ECD loop 4 may act as a selectivity
filter for the incoming agonist. The shape and dynamics of the gate
formed by ECD, TM1, TM2 and ECL1 appear to be linked to ECD
mobility and, in turn, to the interactions between the RAMP linker
and CLR.We speculate that different intramolecular interactions with
CLR differently modulate ECD flexibility. These differences in the
dynamics of loop 4 residues D90ECD, Q93ECD, and D94ECD could
contribute to the selectivity displayed by CLR in complex with the
RAMPs, thus influencing the overall kinetics of binding.
We cannot rule out an involvement of the extracellular surface of
the membrane during the first steps of the association between the
N-terminal domain of CGRPR and TMD extracellular vestibule.
However, the preliminary binding of the peptide C-terminus to
the ECD should restrain the path of the N-terminal domain,
reducing the possibility of diffusion from the membrane.
Simulations of telcagepant highlighted key features and a partial
overlap of association and dissociation paths from the ECD. The
telcagepant binding site is easily accessible from the bulk solvent
without hindrances and presents stable water molecules only in the
proximity of T122ECD, which the phthalimide moiety is likely to
occupy without unfavorable energy contributions thanks to the
hydrogen bonds formed by the amide group. It follows that
desolvation of the pocket should be ruled out as a bottleneck to
binding (Sykes et al., 2019), consistent with the “fast-on” nature of
telcagepant. Our simulations also suggest that the low-nanomolar/
high picomolar affinity of telcagepant for CGRPR is due to the fast
association rather than a long residence time, which is reported to be
close to 2min (Moore et al., 2009).
In summary, we propose an updated scenario for the binding
to CGRPR by the endogenous agonist and a prototypic
antagonist. Exploiting the recent structural information on
different states of the CGRPR (Josephs et al., 2021) and GLP-
1R in the absence of endogenous agonist bound (Wu et al., 2020),
future work will be directed to establishing MD protocols able to
reconstruct the different phases of the proposed two-step binding
mechanism of all class B peptides, taking into account the
conformational transition occurring upon binding.
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